Pluri signs tech transfer, manufacturing agreement with Kadimastem

Pluri announced it has signed a tech transfer and manufacturing agreement with Kadimastem, a clinical stage biotechnology company developing therapeutic cells for ALS and diabetes treatments. PluriCDMO, launched earlier this year, leverages Pluri’s 47,000 square foot good manufacturing practice, or GMP, cell production facility to manufacture cell-based products for life science companies. PluriCDMO will manufacture two cell therapy product candidates for Kadimastem: AstroRx, clinical grade human astrocytes for the treatment of ALS for an upcoming FDA Phase 2a study; and IsletRx, clinical grade pancreatic islet cells which produce and secrete insulin and glucagon in response to blood glucose levels, for the treatment of diabetes.